Congress Must Act Now on FDA User Fees
Thursday, March 29, 2012Joe Brenckle 202-224-2465
WASHINGTON, D.C. – During a hearing today on the Food and Drug Administration’s (FDA) user fee programs, Senator Mike Enzi (R-Wyo.), Ranking Member on the Senate Health, Education, Labor and Pensions (HELP) Committee, emphasized the importance of timely authorization of user fee agreements covering drugs, medical devices, generic drugs, and biosimilar products.
“The prescription drug and medical device user fee agreements expire on September 30 -- six months from now. Congress must act on this crucial legislation in a timely manner,” said Senator Enzi. “Patients, jobs and innovation depend on it.”
Enzi said he and HELP Committee Chairman Harkin plan to mark up one bill containing all four user fee agreements and a small number of bipartisan, consensus policy provisions.
“FDA, industry and other stakeholders have done their jobs by presenting us with proposed user fee agreements,” Senator Enzi said. “Now it’s time for us to do our job, and get a bill enacted.”
Watch Senator Enzi’s opening statement.
# # #
- On 24th ADA Anniversary, Harkin Reflects on Progress, Work Ahead to Ensure All Americans with Disabilities Have the Opportunity to Succeed [Chairman]
- Alexander: States are Leading in Higher Education Innovation, Washington Getting in the Way [Ranking Member]
- Harkin, Miller, Franken: Five Years Since Last Minimum Wage Increase Has Meant $6 Billion Pay Cut for Low-Wage Workers [Chairman]
- Statement of Senator Tom Harkin (D-IA) At the HELP Committee Hearing: “The Role of States in Higher Education” [Chairman]
- HELP Committee Approves Seven Bipartisan Bills, Builds on Record of Accomplishments [Chairman]
- Harkin, Miller, Warren, DeLauro Introduce Legislation to Establish Fair Work Scheduling Practices [Chairman]